Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Clinical trial NCT06918002 · RECRUITING

Trial details

NCT number: NCT06918002
Sponsor: Intergroupe Francophone du Myelome
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma, Newly Diagnosed

Start date: 2025-07-09
Primary completion: 2036-05-01
Enrollment: 824

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.